 | ||
Macimorelin (INN) is a drug being developed by Æterna Zentaris for use in the diagnosis of adult growth hormone deficiency. As of January 2014, it is in Phase III clinical trials. The phase III trial for growth hormone deficiency is expected to be complete in December 2016.
Macimorelin is a mimic of ghrelin, a growth hormone secretagogue. It binds to the growth hormone secretagogue receptor (GHSR) causing release of growth hormone from the pituitary gland.
References
Macimorelin Wikipedia(Text) CC BY-SA